Phase 2 Oesophageal Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older
- People with an advanced or metastatic solid tumour (a cancer that has spread) that has been confirmed by laboratory testing of tissue, and that has come back or stopped responding to standard treatments — or where no standard treatment exists
- People whose cancer can be measured using standard imaging guidelines (known as RECIST v1.1 or iRECIST)
- People who are generally well enough to carry out everyday activities, with a performance level that falls within the range the trial accepts (confirm specific level with trial site)
- People whose blood counts, kidney function, liver function, heart function, and oxygen levels meet the trial's minimum thresholds (the trial site will assess these through blood tests and other checks)
- People who have brain metastases (cancer that has spread to the brain) only if those areas have been stable for at least 3 months and do not currently require increasing doses of steroids to manage them
Who may not be able to join:
- People who are pregnant or breastfeeding
- People who need ongoing systemic (whole-body) medications that suppress the immune system, such as steroid tablets above a low dose, during the treatment period (some inhaled or skin-applied versions may be permitted — confirm with trial site)
- People with an active autoimmune disease that requires systemic immune-suppressing treatment
- People with an uncontrolled bacterial, fungal, or viral infection
- People who have received another experimental treatment within 28 days before the first dose in this trial
- People who have received a live vaccine within 6 weeks before the preparatory treatment phase of the trial
- People who are HIV positive, or who have active hepatitis B or C with detectable virus levels in their blood (some cases of chronic, symptom-free hepatitis may be considered — confirm with trial site)
- People with a known allergy to any ingredient in the trial treatment, such as albumin or DMSO
- People with any medical or personal circumstances that the trial team considers likely to affect safe participation or the ability to follow the trial requirements
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 2077706670
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs); Incidence of Dose-Limiting Toxicities (DLTs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.